AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
Two different dosing regimens demonstrated efficacy with one showing a better profile No hospitalisations or severe cases of COVID-19 in participants treated with AZD1222Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. There were a total of 131 COVID-19 cases in the interim analysis. One dosing regimen (n=2,741) showed vaccine efficacy of